Cargando…

A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response

Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamil, Maria, Daneshvar, Amir, Nachawati, Dana, El Sharu, Husam, Meysami, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404464/
https://www.ncbi.nlm.nih.gov/pubmed/37551226
http://dx.doi.org/10.7759/cureus.41524
_version_ 1785085304974082048
author Jamil, Maria
Daneshvar, Amir
Nachawati, Dana
El Sharu, Husam
Meysami, Alireza
author_facet Jamil, Maria
Daneshvar, Amir
Nachawati, Dana
El Sharu, Husam
Meysami, Alireza
author_sort Jamil, Maria
collection PubMed
description Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness and tenderness in her upper and lower extremities, following a single dose of zoledronic acid infusion for the treatment of osteoporosis. The onset of symptoms occurred one week after the infusion and persisted, progressively worsening over time, leading to functional impairment and the need for a walker for ambulation. Laboratory studies revealed an elevated erythrocyte sedimentation rate while other autoimmune markers were within normal limits. Differential diagnosis included an adverse reaction to zoledronic acid or underlying polymyalgia rheumatica. The patient showed significant improvement with a prednisone taper, suggesting an immune-mediated response. This case highlights the importance of considering severe immune reactions as a potential side effect of zoledronic acid and emphasizes the need for further research to better understand the underlying mechanisms and optimize patient management.
format Online
Article
Text
id pubmed-10404464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104044642023-08-07 A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response Jamil, Maria Daneshvar, Amir Nachawati, Dana El Sharu, Husam Meysami, Alireza Cureus Endocrinology/Diabetes/Metabolism Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness and tenderness in her upper and lower extremities, following a single dose of zoledronic acid infusion for the treatment of osteoporosis. The onset of symptoms occurred one week after the infusion and persisted, progressively worsening over time, leading to functional impairment and the need for a walker for ambulation. Laboratory studies revealed an elevated erythrocyte sedimentation rate while other autoimmune markers were within normal limits. Differential diagnosis included an adverse reaction to zoledronic acid or underlying polymyalgia rheumatica. The patient showed significant improvement with a prednisone taper, suggesting an immune-mediated response. This case highlights the importance of considering severe immune reactions as a potential side effect of zoledronic acid and emphasizes the need for further research to better understand the underlying mechanisms and optimize patient management. Cureus 2023-07-07 /pmc/articles/PMC10404464/ /pubmed/37551226 http://dx.doi.org/10.7759/cureus.41524 Text en Copyright © 2023, Jamil et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Jamil, Maria
Daneshvar, Amir
Nachawati, Dana
El Sharu, Husam
Meysami, Alireza
A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title_full A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title_fullStr A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title_full_unstemmed A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title_short A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
title_sort rare presentation of zoledronate-induced systemic inflammatory response
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404464/
https://www.ncbi.nlm.nih.gov/pubmed/37551226
http://dx.doi.org/10.7759/cureus.41524
work_keys_str_mv AT jamilmaria ararepresentationofzoledronateinducedsystemicinflammatoryresponse
AT daneshvaramir ararepresentationofzoledronateinducedsystemicinflammatoryresponse
AT nachawatidana ararepresentationofzoledronateinducedsystemicinflammatoryresponse
AT elsharuhusam ararepresentationofzoledronateinducedsystemicinflammatoryresponse
AT meysamialireza ararepresentationofzoledronateinducedsystemicinflammatoryresponse
AT jamilmaria rarepresentationofzoledronateinducedsystemicinflammatoryresponse
AT daneshvaramir rarepresentationofzoledronateinducedsystemicinflammatoryresponse
AT nachawatidana rarepresentationofzoledronateinducedsystemicinflammatoryresponse
AT elsharuhusam rarepresentationofzoledronateinducedsystemicinflammatoryresponse
AT meysamialireza rarepresentationofzoledronateinducedsystemicinflammatoryresponse